Free Trial

Greenwich LifeSciences Q1 2024 Earnings Report

Greenwich LifeSciences logo
$12.39 -0.13 (-1.04%)
(As of 12/20/2024 05:31 PM ET)

Greenwich LifeSciences EPS Results

Actual EPS
-$0.19
Consensus EPS
-$0.20
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Greenwich LifeSciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Greenwich LifeSciences Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

WARNING: “Buffett Indicator” flashing for first time in 50 years (Ad)

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW

Greenwich LifeSciences Earnings Headlines

Greenwich LifeSciences Partners With Breast C...
Greenwich LifeSciences Partners with GIM in Italy
Is Starlink Set For The Largest IPO In History?
He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000!
Greenwich LifeSciences Provides Update on Corporate Events
See More Greenwich LifeSciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Greenwich LifeSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Greenwich LifeSciences and other key companies, straight to your email.

About Greenwich LifeSciences

Greenwich LifeSciences (NASDAQ:GLSI), a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

View Greenwich LifeSciences Profile

More Earnings Resources from MarketBeat

Upcoming Earnings